What Co Tareg Treats: Main Uses and Benefits

Co Tareg is commonly used to help with symptoms related to heightened physiological activity in adult patients. The drug is relevant in contexts marked by increased discomfort or tension, applied in clinical settings that involve acute or unstable symptom patterns. It is considered relevant when multiple therapeutic approaches are considered appropriate to achieve and maintain stabilization. The primary domains involve conditions characterized by periods of heightened symptoms, including essential hypertension and refractory blood pressure elevation.

---

This medication plays a role in managing symptoms that create noticeable physiological strain and assists with reducing the chronic strain that persistently elevated blood pressure places on the heart, arteries, and other vital organs. By providing a comprehensive antihypertensive effect, Co Tareg contributes to easing the overall symptom load associated with cardiovascular stress.

---

Quick Fact: Relief for Persistent Blood Pressure Elevation

Regulatory References

1. NIH DailyMed Label on Indications and Benefits

Population Eligibility for Co Tareg

Official regulatory guidelines strictly define the population groups eligible for Co Tareg (Valsartan/Hydrochlorothiazide) use. The medicine is primarily indicated for adult patients whose blood pressure is not controlled by single-component therapies.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited for several specific patient groups:

• Pregnant Women: Contraindicated, especially during the second and third trimesters, due to risk of fetal harm.
• Severe Organ Dysfunction: Contraindicated in patients with anuria (inability to produce urine), severe hepatic impairment, biliary cirrhosis, cholestasis, and severe renal impairment (Creatinine Clearance <30 mL/min).
• Allergy: Contraindicated in patients with a known hypersensitivity to the active ingredients or to any sulfonamide-derived medicines.
• Drug Interaction: Contraindicated with concomitant use of aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Restricted and Conditional Use

The medicine is not recommended for children and adolescents under the age of 18, as safety and efficacy have not been established in this age group. Use is also not recommended for nursing women. Patients who are volume- or salt-depleted, or those with a history of angioedema related to past blood pressure medication, require special consideration and caution.

The interaction profile for Co Tareg (Valsartan/Hydrochlorothiazide) is defined by documented prohibitions and specific alterations to drug exposure and effect, strictly based on regulatory labeling.

Formal Restrictions and Contraindications

A major contraindication exists for co-administration with Aliskiren in patients with diabetes due to the risk of severe hypotension, hyperkalemia, and renal impairment from dual RAS inhibition. Use is also restricted in patients with anuria or severe impairment of hepatic or renal function (creatinine clearance less than 30 mL/min).

Pharmacokinetic and Pharmacodynamic Interactions

Exposure-altering interactions occur when the valsartan component is co-administered with drug transporter inhibitors, such as Rifampin or Ciclosporine, which may increase the valsartan's systemic levels. Conversely, Cholestyramine and Colestipol reduce the absorption of the hydrochlorothiazide component.

Pharmacodynamic interactions include an increased risk of lithium toxicity due to reduced renal clearance by the thiazide component. The combination with NSAIDs may reduce the antihypertensive effect and increase the risk of renal function deterioration. Co-use with Potassium Supplements or Potassium-Sparing Diuretics significantly increases the documented risk of hyperkalemia (elevated serum potassium levels).

Administration Timing Rule

To manage the absorption-reducing interaction, the hydrochlorothiazide component must be administered at least 4 hours before or 4–6 hours after the administration of the bile-acid binding resins, such as Cholestyramine or Colestipol.

Blocking Angiotensin II Receptors

Valsartan, an Angiotensin II Receptor Blocker (ARB), acts as a competitive antagonist at the Angiotensin II type 1 ( AT1 ) receptor. By binding selectively to the AT1 receptor, valsartan inhibits the actions of Angiotensin II. This action modulates key pathways in the Renin-Angiotensin-Aldosterone System (RAAS), initiating a sequence that limits receptor-mediated vasoconstriction and decreases aldosterone-mediated sodium and water reabsorption in the renal tubules. The cascade results in the relaxation of vascular smooth muscle and a resulting shift toward diminished extracellular fluid volume.

---

Modulating Renal Electrolyte Transport

Hydrochlorothiazide (HCTZ), a thiazide diuretic, modulates fluid balance by targeting the distal convoluted tubules of the kidney. It exerts its effect by inhibiting the Na^+- Cl^- cotransporter, a membrane protein responsible for solute reabsorption. This inhibition modifies early molecular steps in the nephron's transport process, increasing the renal excretion of both sodium and chloride, leading to an osmotically driven rise in water loss. This mechanism alters fluid dynamics and pressure within the systemic circulatory system.

Co Tareg (valsartan/hydrochlorothiazide) is prescribed as an oral solid dosage form exclusively for adult patients managing hypertension. The administration is strictly oral using the film-coated tablet, which is designed for a once-daily (qDay) dosing regimen. Patients are instructed to take the tablet at the same time each day, preferably in the morning. The tablets may be taken with or without food but must be swallowed whole with water, as they are generally non-divisible.

---

The official strategy for this medication is typically as a replacement or add-on therapy for patients whose blood pressure is not adequately controlled by treatment with a single component. The usual initial dose when switching to the combination is commonly 160 mg Valsartan / 12.5 mg Hydrochlorothiazide once daily. Doses are determined by the fixed-strength tablets available, and the maximum recommended daily dose is constrained to 320 mg Valsartan / 25 mg HCTZ.

---

Dose adjustment, or titration, should be considered only after a period of approximately four weeks, as this duration is required for the maximal antihypertensive effect to be attained following a change in regimen. The official use protocol also includes constraints for specific populations: the medication is not recommended for use in patients under 18 years old. Furthermore, patients with severe renal impairment (creatinine clearance less than 30 mL/min) or severe hepatic impairment are typically advised against this combination therapy. In the event of a missed dose, the patient should skip the missed tablet and take the next scheduled dose at the usual time; doubling the dose is not permitted.

Research Evidence / Overview of Studies for Co Tareg

Evidence for Use in Uncontrolled High Blood Pressure

The clinical evaluation of Co Tareg was studied for its use in high blood pressure, particularly in adults whose pressure was not controlled when taking a single agent alone. The core evidence was studied in short-term Randomized Controlled Trials (RCTs). These studies compared the combination tablet directly against the use of its individual components (Valsartan alone or Hydrochlorothiazide alone), as well as against an inactive placebo.

The primary focus of these trials was to monitor outcomes monitoring physiological strain or stress, specifically measuring the change from the start of the study in Systolic and Diastolic Blood Pressure (SBP/DBP) readings. Studies described patterns where the magnitude of blood pressure change was different when the two components were administered together compared to the components used individually. Research also described patterns where the proportions of participants on the combination therapy reaching predefined target blood pressure goals were different from those on the single components. This evidence contributes to the broader evidence landscape for dual-component therapies in hypertension.

Long-Term Studies and Cardiovascular Follow-up

Research has also explored whether observations from blood pressure studies correlate with long-term health outcomes. Dedicated long-term trials (lasting several years) focusing specifically on the fixed-dose combination product itself to assess fatal or nonfatal cardiovascular events (such as stroke or heart attack) are not fully established.

Instead, long-term outcomes for the combination are often viewed in the context of research that monitored the component drug classes individually. Studies of the Angiotensin II Receptor Blocker and Thiazide Diuretic classes show patterns related to cardiovascular outcomes when used in research contexts involving fluctuating or unstable symptoms. These findings help contextualize the long-term evidence landscape, although direct long-term effects are not fully established for the specific fixed-dose combination product.

Research in Special Patient Populations

The main clinical trials was evaluated in adult patients (ge18 years of age) with essential hypertension. Therefore, results apply only to the populations studied. Research was studied for the use of the combination therapy in these adult groups, including those whose symptoms were observed in some studies to be more unstable or who presented with systemic or functional imbalance due to elevated pressure.

However, data for certain groups remain insufficient. For instance, research exploring use in pediatric patients (under 18) is not established, as this group was generally excluded from the core clinical trials. Additionally, while certain studies monitored the drug's use in adult patients with varying degrees of renal or hepatic impairment, the overall evidence quality varies across studies, and data for certain groups remain insufficient.

Key Limitations and Remaining Evidence Gaps

The existing research landscape highlights several areas where data are still emerging or where evidence is limited. One key limitation is that follow-up durations were limited in the core trials, meaning the primary evidence focuses on short-term blood pressure control (typically 8 to 12 weeks).

Furthermore, the most significant limitation is the limited information for long-term outcomes regarding hard cardiovascular endpoints specifically for the fixed-dose combination itself. This connection is currently based on extrapolation rather than direct, long-term FDC-specific trials. Finally, the absence of data regarding use in pediatric patients also represents a significant research gap.

Key Studies & References

1. Label: DIOVAN HCT - hydrochlorothiazide, valsartan tablet, film coated (FDA DailyMed)
2. JNC 8 Hypertension Guideline Algorithm (Used for establishing class use and combination rationale)

Common questions about Co Tareg (FAQ)

Q: Is Co Tareg the same as taking two separate pills?

Co Tareg is described in official product information as a fixed-dose combination product, meaning it contains both active ingredients in a single tablet. This approach is intended to help optimize patient adherence compared to taking the two components separately.

---

Q: What are the most common things people feel when they start taking Co Tareg?

Regulatory documents state that the most common adverse reactions reported in clinical trials include dizziness, headache, and fatigue. Symptoms of upper respiratory tract infections, such as nasopharyngitis, are also commonly reported.

---

Q: Can Co Tareg cause tiredness or fatigue?

Yes, fatigue is listed in official documentation as one of the commonly reported adverse reactions in clinical trials.

---

Q: Is a slight dizziness common with Co Tareg?

Yes, dizziness is listed in official product information as one of the commonly reported adverse reactions. This is often related to the medicine's effect on blood pressure.

---

Q: Does Co Tareg interact with common pain relievers like ibuprofen?

Official documents state the combination may interact with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. This interaction could potentially reduce the medicine's blood pressure-lowering effect and may increase the risk of affecting kidney function.

---

Q: Does Co Tareg affect kidney function over time?

The medication is not recommended for patients who already have severe renal impairment. Additionally, official documents advise monitoring kidney function when using certain interacting medicines together with Co Tareg.

---

Q: Why does Co Tareg use two different kinds of ingredients?

The medicine is a fixed-dose combination designed to combine two different mechanisms of action. It is described as aiming for a comprehensive blood pressure-lowering effect by including valsartan (which blocks a substance that tightens blood vessels) and hydrochlorothiazide (a diuretic that helps remove excess salt and water).

---

Q: Does Co Tareg interact with lithium?

Yes, regulatory documentation describes an increased risk of lithium toxicity when used with this medication. This is because the hydrochlorothiazide component may reduce the kidney's ability to clear lithium from the body.

---

Q: Is Co Tareg known to affect potassium levels?

Official information states the medicine may cause shifts in the body's electrolyte balance. This includes the potential for both high potassium (hyperkalemia) and low potassium (hypokalemia).

---

Q: Why is it important to check potassium levels while on Co Tareg?

Monitoring is necessary because the medicine has the potential to cause shifts in potassium levels, which can lead to fluid or electrolyte imbalance. This vigilance helps manage the documented risks of both hyperkalemia and hypokalemia.

---

Q: Does Co Tareg affect blood sugar levels?

The Hydrochlorothiazide component (the diuretic) is described in official information as having the potential to increase blood sugar levels. Official documents indicate this potential may necessitate closer monitoring in patients with diabetes.

---

Q: What is the long-term safety profile of Co Tareg described as in official sources?

The primary clinical trials for the specific combination product focused on blood pressure control over short periods (typically 8 to 12 weeks). Long-term health outcomes for the specific combination are generally viewed in the context of research that tracked the individual component drug classes.

---

Q: What are the rules about using Co Tareg and alcohol?

Official documents state that alcohol may cause blood pressure to fall further and can make side effects, such as dizziness or feeling faint, worse.

---

Q: What are the common high-level themes reported in research on Co Tareg?

Research themes focus on the combination's ability to lower systolic and diastolic blood pressure, and that the blood pressure reduction achieved was different (typically greater) than when the two components were used individually.

---

Q: Can Co Tareg cause sensitivity to the sun?

Official documentation describes the medication as potentially increasing the skin's sensitivity to sunlight. Due to this documented potential, precautions such as using sunscreen and wearing protective clothing are generally mentioned in patient materials.

---

Q: What happens if I stop taking Co Tareg suddenly?

Official patient information states that stopping the medicine is not advised without the involvement of a healthcare provider. Any decision to stop or change this treatment must be managed by a healthcare provider.

---

Q: Are there any foods I should avoid while using Co Tareg?

The medicine affects potassium levels. Official patient guidance recommends discussing the use of salt substitutes containing potassium with a healthcare provider before using them.

---

Q: Can I take Co Tareg if I am already taking supplements?

Official patient guidance advises disclosing the use of any medications, as well as any supplements, herbs, or vitamins being taken, to a healthcare provider.

---

Q: What is the risk of Co Tareg causing a cough compared to other blood pressure medicines?

Cough is listed as an Uncommon adverse reaction in the regulatory documents. The Valsartan component belongs to a class of medicines (Angiotensin II Receptor Blockers) that is generally associated with a low incidence of cough.

---

Q: Can Co Tareg cause dry mouth?

Dry mouth is listed in official documentation as a symptom that requires prompt reporting, as it may be a sign of fluid or electrolyte imbalance, which the medicine can affect.

---

Q: Can Co Tareg cause muscle cramps?

Muscle spasms are listed in official documents as a commonly reported adverse reaction. Muscle cramps are also listed as a potential symptom of fluid or electrolyte imbalance, which is a key documented effect of the medicine.

---

Q: Is Co Tareg effective for people who are overweight?

Clinical trials have included the study of the combination in obese, hypertensive patients. The findings have been described as showing similar blood pressure-lowering patterns in this population.

---

Q: Does taking Co Tareg mean I have to limit my salt intake?

The medicine works, in part, to remove excess salt and water. Official patient guidance states that any low-salt or low-sodium diet instructions given by a healthcare provider should be followed as part of the overall treatment plan.

---

Q: How long does the effect of one dose of Co Tareg last?

The blood pressure-lowering effect of the Valsartan component is described in documents as persisting for 24 hours. The Hydrochlorothiazide component's diuretic effect typically lasts between 6 and 12 hours.

---

Q: Is Co Tareg available in a generic form?

Yes, the fixed-dose combination of the active ingredients, valsartan and hydrochlorothiazide, is officially approved and available in generic form from multiple manufacturers.

---

Q: Why do some people switch from separate pills to Co Tareg?

The combination product is often used as a replacement for the individual components. The fixed-dose approach is generally described as a strategy intended to help optimize patient adherence by simplifying the daily regimen.

---

Q: Are there any known interactions between Co Tareg and herbal supplements?

Official patient guidance advises disclosing the use of any herbal remedies, vitamins, or supplements being taken to a healthcare provider. This is because their specific interactions with Co Tareg are not fully tested or established.

---

Q: Do patients need to have their blood pressure monitored frequently when starting Co Tareg?

Regulatory information indicates that the clinical response to the medicine is described as being evaluated after initiating therapy. Blood pressure is monitored to determine if the dose needs to be adjusted after a set period.

---

Q: Can Co Tareg be used by people with asthma?

Regulatory information notes that sensitivity reactions related to the hydrochlorothiazide component may occur in patients with or without a history of bronchial asthma. This is a point for special consideration.

---

Q: What if I take Co Tareg too close to bedtime?

Official guidance states the medicine should be taken once daily, preferably in the morning. This timing is recommended to manage the diuretic effect of the hydrochlorothiazide component, which can last up to 12 hours.

---

Q: Is Co Tareg safe for people who drive or operate machinery?

Official warnings state that the medicine may cause dizziness, lightheadedness, and fainting, especially when first starting. The potential for these effects is a factor to consider when performing tasks such as driving or operating machinery.

---

Q: Does Co Tareg interact with common cold or flu medications?

The medicine may interact with certain components often found in cold or flu remedies. This includes NSAIDs (pain relievers) and sympathomimetic agents (found in decongestants), which may affect blood pressure or involve potential cardiovascular risks.

---

Q: What is the typical age range of people using Co Tareg in studies?

Clinical trials for the medicine's use in high blood pressure primarily evaluated adult patients (aged 18 and older). Study data also included significant observation in the elderly population.

How to Store and Dispose of Co Tareg

The official labeling for Co-Tareg (valsartan/hydrochlorothiazide) tablets strictly defines the required storage and disposal procedures to maintain product stability.

Storage Requirement	Condition
Temperature	Store at room temperature, typically 59 F to 86 F (15 C to 30 C).
Protection	Keep in a closed container in a dry place, away from excess heat, light, and moisture.
Packaging	Must be kept in the original container and tightly closed.

Co-Tareg must be stored out of the reach and sight of children. To dispose of unused or expired tablets, use an authorized drug take-back program. If a program is unavailable, follow specific FDA instructions for mixing the medicine with an unappealing substance, sealing it in a bag, and discarding it in the household trash; do not dispose of it in wastewater.